Walgreens Boots Alliance, Inc.

Equities

WBA

US9314271084

Drug Retailers

Real-time Estimate Cboe BZX 15:16:07 02/07/2024 BST 5-day change 1st Jan Change
11.46 USD -1.08% Intraday chart for Walgreens Boots Alliance, Inc. -26.56% -55.84%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
You can't escape politics Our Logo
RBC Cuts Price Target on Walgreens Boots Alliance to $13 From $22, Keeps Sector Perform Rating MT
ANALYST RECOMMENDATIONS : Adobe, Nike, Solaredge, Welltower, Spectris... Our Logo
Nasdaq Closes at Record High as Markets Evaluate Manufacturing Data MT
Nasdaq Closes at Record High as Markets Evaluate Manufacturing Sector Data MT
Sector Update: Health Care Stocks Retreat Late Afternoon MT
US Equities Markets End Higher Monday as Investors Parse Manufacturing Sector Data MT
Sector Update: Health Care MT
Equity Markets Rise Intraday as Traders Analyze Manufacturing Sector Data MT
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity MT
Correction: Market Chatter: Walgreens Boots Alliance's Boots Unit Sees Top Executive Step Down MT
Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity MT
BofA Securities Cuts Price Target on Walgreens Boots Alliance to $11 From $12, Maintains Underperform Rating MT
Walgreens Boots Alliance Chief Executive to Resign MT
TD Cowen Adjusts Price Target on Walgreens Boots Alliance to $22 From $35, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on Walgreens Boots Alliance to $20 From $30, Maintains Overweight Rating MT
ANALYST RECOMMENDATIONS : Nvidia, Broadcom, Progressive, Draftkings, Moody's... Our Logo
Boots CEO Sebastian James to stand down AN
Boots CEO James quits after Walgreens' plans for sale stalls, Sky News reporter says RE
Boots Chief Quits Reportedly After Walgreens' Sale Plan Stalls CI
Walgreens' Q3 Earnings Miss Reflects Weak Consumer Spending, Pharmacy Headwinds, Morgan Stanley Says MT
Walgreens' Earnings Guidance Cut Implies 'Notably Weaker' Fourth Quarter, Morgan Stanley Says MT
Walgreens Boots Alliance's Fiscal Q3 Results Reflect Pharmacy Headwinds, Challenging Retail Environment, Truist Securities Says MT
BofA Securities Slashes Price Target on Walgreens Boots Alliance to $11 From $22, Maintains Underperform Rating MT
Truist Cuts Price Target on Walgreens Boots Alliance to $13 From $20, Calls Fiscal Q3 'Difficult,' Keeps Hold Rating MT
Chart Walgreens Boots Alliance, Inc.
More charts
Walgreens Boots Alliance, Inc. specializes in the distribution of pharmaceutical products. Net sales break down by activity as follows: - retail distribution (87.2%): selling prescription drugs, OTC medicines, beauty and cosmetic products, etc. in the United States (90.9% of net sales) and internationally (9.1%). At the end of August 2023, the activity is carried out through 13,532 outlets (of which 8,706 located in the United States, Puerto Rico and the US Virgin Islands), and through the Internet; - wholesale distribution (8.1%). The remaining sales (4.7%) are from the healthcare Net sales break down geographically as follows: the United States (84%), Germany (8.1%), the United Kingdom (6.5%) and other (1.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
11.58 USD
Average target price
15.08 USD
Spread / Average Target
+30.25%
Consensus
  1. Stock Market
  2. Equities
  3. WBA Stock
  4. News Walgreens Boots Alliance, Inc.
  5. RBC Capital Cuts Walgreens Boots Alliance's Price Target to $22 From $26, Sector Perform Rating Kept